[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100507563":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":26,"locations":35,"responsibleParty":54,"collaborators":56,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":65,"eligibilityCriteria":66,"healthyVolunteers":61,"sex":67,"minAge":68,"maxAge":10,"enrollmentInfo":69,"targetDuration":72,"studyType":73,"phases":10,"briefSummary":74,"conditions":75,"keywords":77,"overallStatus":38,"whyStopped":10,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Connecticut Children's Medical Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Nasal Nitric Oxide",null,"Participants who are referred by his\u002Fher clinician for nasal NO testing and meet the inclusion and exclusion criteria will undergo testing. Clinical information regarding prior diagnostic testing will be collected at time of enrollment. Participants that have a confirmed diagnosis of PCD by genetics or ciliary biopsy at time of study entry",[13],"Device: Nasal Nitric Oxide testing",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DEVICE","Nasal Nitric Oxide testing","Collection of already performed clinical data and nNO testing",[9],[21],"nNO testing",[23],{"name":24,"affiliation":5,"role":25},"Melanie S Collins, MD","PRINCIPAL_INVESTIGATOR",[27,31],{"name":24,"role":28,"phone":29,"phoneExt":10,"email":30},"CONTACT","860-545-9440","mcollin@connecticutchildrens.org",{"name":32,"role":28,"phone":33,"phoneExt":10,"email":34},"Sigrid M Almeida, BS","8608375343","salmeida@connecticutchildrens.org",[36],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Pulmonary Division","RECRUITING","Hartford","Connecticut","06111","United States","US",{"type":45,"coordinates":46},"Point",[47,48],-72.68509,41.76371,{"lat":48,"lon":47},[51,53],{"name":24,"role":28,"phone":52,"phoneExt":10,"email":30},"8605459440",{"name":32,"role":28,"phone":33,"phoneExt":10,"email":34},{"type":55,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[57],{"name":58,"class":6},"UConn Health","100507563","utility-of-pcd-diagnostics-to-improve-clinical-care-100507563",false,"NCT05889013","Utility of PCD Diagnostics to Improve Clinical Care","A Clinical Study to Gather Data on the Utility of Tests That Are Used to Make a Diagnosis of Primary Ciliary Dyskinesia (PCD)","PCD","Inclusion Criteria:\n\n* Age ≥ 2 years of age\n* Must have two of the following clinical history points:\n* Neonatal respiratory distress\n* Chronic nasal congestion\u002Frunny nose\n* Chronic cough\n* Situs\u002Flaterality defects\n* Bronchiectasis\n* Ability to provide informed consent or consent of parent\u002Fguardian and ass\n\nExclusion Criteria:\n\n* Recent history of sinus surgery or bloody nose in the past week\n* Age \\\u003C 2 years of age\n* Inability to tolerate probe in nose\n* Sinusitis or other respiratory exacerbation currently being treated with antibiotics\n* Admitted to hospital for respiratory exacerbation (inpatient status)\n* Inability to understand the requirements of the study or be unwilling to provide written informed consent (as evidenced by signature on an informed consent document approved by the IRB)\n* Any other reason for which the study investigators feel the patient is not a good candidate to complete the testing","ALL","2 Years",{"count":70,"type":71},50,"ESTIMATED","3 Years","OBSERVATIONAL","This cross-sectional and longitudinal observational study is to gather data on the utility of tests that are used to make a diagnosis of primary ciliary dyskinesia (PCD). There is new testing available, called nasal nitric oxide testing, that non-invasively measures nitric oxide levels in the sinus cavity. Individuals with PCD characteristically have low levels, but this testing does not have extensive data from everyday clinical practice. The objective of this proposal is to improve the diagnostic approach to children and adults with clinical concerns for primary ciliary dyskinesia (PCD).",[76],"Primary Ciliary Dyskinesia",[65,78],"nasal nitric oxide testing","2025-09-19",{"date":81,"type":82},"2025-09-22","ACTUAL",{"date":84,"type":82},"2023-10-17",{"date":86,"type":71},"2028-12",{"name":5,"class":6},1]